4 minute read
HAZARDOUS MEDICINAL PRODUCTS SESSION
SIG LAUNCH
Advertisement
ACPE UAN: 0475-0000-22-020-L03-P – An knowledge-based activity.
Session: Wednesday, 23 March 2022, from 17.15 to 18.45 Room: Room -2.31
Facilitator: Ana Valladolid Walsh Presenters: Joan Peppard, Falko Schüllner
No conflict of interest declared. Please reference speakers’ biographies.
LINKED TO EAHP STATEMENTS
Section 3 – Production and Compounding: Statements 3.3, 3.4, 3.5, 3.6 Section 5 – Patient Safety and Quality Assurance: Statements 5.6, 5.9
ABSTRACT
Hospital pharmacists and members of the multidisciplinary team – such as nurses, pharmacy technicians and others – are dealing with hazardous medicinal products in their daily work. Their safe handling is of uttermost importance for the safety of healthcare professionals and patients treated with these medicines. Their classification plays an essential role in determining suitable handling procedures. However, unlike the United States, Europe does not have one single body similar to the National Institute for Occupational Safety and Health (NIOSH) that addresses all questions linked to the classification of hazardous medicinal products. To better understand the classification landscape for hazardous medicinal products in Europe, the European Association of Hospital Pharmacists (EAHP) has established a Special Interest Group (SIG). EAHP’s SIG on Hazardous Medicinal Products discussed and gathered information on the current status of hazardous medicinal product classification in European countries as well as their similarities and differences, put together a definition of the term ‘hazardous medicinal product’ for Europe and reflected on the protection of healthcare professionals and patients from exposure to hazardous medicinal products. Specific focus was put on the NIOSH model which is used by many European countries and the Dutch model (Risico instrument Farmaceutische Stoffen (RiFaS) – Pharmaceutical Substances Risk Assessment). ‘Hazardous medicinal products’ were addressed in a wide sense including but not limited to carcinogenic, mutagenic or toxic to reproduction (CMR) drugs, some of the immunomodulators and biological substances. Based on their findings and discussion outcomes the SIG developed recommendations and guidance to support hospital pharmacists and their advocacy work linked to protocols around classification, storage, and handling of potentially hazardous medicinal products. This session will be dedicated to sharing the results of the work carried out by EAHP’s SIG on Hazardous Medicinal Products throughout 2021, including the European-developed classification model recommended by the SIG.
LEARNING OBJECTIVES
After the session, participants should be able to: • Recognise different classification models for hazardous medicinal products identified by the SIG (e.g. NIOSH, the Dutch model), including their strengths and weaknesses • Identify hazardous medicinal products with the help of a proposed European definition and the Europeandeveloped classification model recommended by the SIG • Discuss protocols around the classification, storage, and handling of potentially hazardous medicinal products.
EDUCATIONAL NEED ADDRESSED
The classification of hazardous medicinal products is largely influenced by NIOSH. EAHP’s SIG has closed gaps by identifying classification systems around Europe and creating a European model a definition of the term ‘hazardous medicinal products’ applicable to the European treatment landscape.
Please come and visit us on our STAND N°2
CUSTOMIZED SOLUTIONS FOR ASEPTIC PROCESS
Applications in Hospital Pharmacy
JCE Customized Solutions and Systems with more than 29 years’ experience Several countries have already trusted us: Belgium, Switzerland, Austria, Poland, Italy, China, Vietnam ...
Range of isolators with specific applications in hospital pharmacy :
• Reconstitution of cytotoxic drugs or monoclonal antibodies Reconstitution of cytotoxic drugs or monoclonal antibodies • Preparation of parental nutrition Preparation of dry forms Preparation of parental nutrition Preparation of dry forms • Weighing and dosing Clinical trials Weighing and dosing Clinical trials • Hematology and Immunology Bacteriology and Virology Hematology and Immunology Bacteriology and Virology • Secure RTP Transfer Systems Secure RTP Transfer Systems
- Bio-decontamination with peracetic acid or hydrogen peroxide - Physical and bacteriological validation & system qualification - Large range of accessories and disposables
Secure Transfer of potentially Infections and related Medical Waste, including Sharp Items and Toxic Waste
JCE Multiway System ® MWS A 150® Transfer Door
• Patented RTP connection Patented RTP connection system system • Secure transfer door Secure transfer door • Introduction diameter : Introduction diameter : • 150 mm150 mm • Made out of 316 L stainless Made out of 316 L stainless steel or PVC steel or PVC • Max. air pressure Max. air pressure • allowed > 500 Pa. allowed > 500 Pa. • Suitable with all types of Suitable with all types of isolatorsisolators
CTR 150 050 ® Waste Container
• Rigid HDPE ContainerRigid HDPE Container • Real Capacity : 55 LReal Capacity : 55 L • 25 kGy gamma irradiated 25 kGy gamma irradiated • Suitable for incineration Suitable for incineration • Complies with theComplies with the • standards governing standards governing • the Transfer of potentially the Transfer of potentially • Infectious and related Infectious and related • Medical Waste, including Sharp Medical Waste, including Sharp
ItemsItems • Complies with NF X 30-511 / UN Complies with NF X 30-511 / UN 3249 / UN 32913249 / UN 3291 • Easy to useEasy to use
JCE BIOTECHNOLOGY
www. jcebiotechnology .com
